A. Gibb

发表

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

A. Pettitt, J. Radford, M. Ranson, 2013, British Journal of Cancer.

Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response‐adapted design in the first‐line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY)

J. Radford, S. Barrington, A. Davies, 2020, British journal of haematology.

Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma

Sam A. Mayes, T. Illidge, A. Gibb, 2012 .

Outcomes following front-line chemotherapy in peripheral T-cell lymphoma: 10-year experience at The Royal Marsden and The Christie Hospital

M. Gleeson, J. Radford, A. Wotherspoon, 2018, Leukemia & lymphoma.

Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin

J. Radford, M. Howell, K. Linton, 2017, British journal of haematology.

The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors.

J. Ogden, N. Anderson, A. Gibb, 1997, Neuropsychiatry, neuropsychology, and behavioral neurology.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis

R. Clifford, A. Hayat, P. McKay, 2021, British journal of haematology.

Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center

J. Radford, T. Illidge, K. Linton, 2013, Haematologica.

Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma.

S. Booth, J. Willan, P. Fields, 2020, Blood advances.

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma

R. Advani, R. Bouabdallah, H. Tilly, 2015, Leukemia & lymphoma.

RESULTS OF a PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)

J. Radford, V. Warbey, P. McKay, 2017 .

Results of a multicentre UK‐wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting

C. Burton, J. Radford, K. Ardeshna, 2017, British journal of haematology.

CAR T in patients with large B‐cell lymphoma not fit for autologous transplant

E. Tholouli, T. Menne, C. Jones, 2023, British Journal of Haematology.

Gamma–delta T-cell lymphoma of skin, eye and brain presenting with visual loss

S. Coupland, L. Irion, N. Jones, 2017, BMJ Case Reports.